子宫内膜癌市场 - 全球产业规模、份额、趋势、机会及预测（按癌症类型、治疗方法、诊断方法、最终用途、地区和竞争格局划分，2021-2031年）

全球子宫内膜癌市场预计将从 2025 年的 309 亿美元成长到 2031 年的 443.1 亿美元，年复合成长率为 6.19%。

该市场涵盖多种诊断工具和治疗方案，包括手术、化疗、放射线治疗和药物治疗，旨在治疗子宫内膜恶性肿瘤。推动市场成长的关键因素包括全球肥胖和METABOLIC INC.发病率的上升（这是主要风险因素），以及女性人口老化（女性更容易罹患肿瘤疾病）。此外，标靶药物疗法和免疫疗法的出现显着拓宽了復发性或转移性疾病患者的治疗选择范围。根据美国癌症协会的数据，预计2024年美国将新增67,880例宫癌病例，凸显了对有效治疗策略日益增长的临床需求。

儘管取得了这些进展，但由于新型生物製药和免疫查核点抑制剂的高昂成本，市场仍面临许多障碍。在医疗体系注重成本控制的地区，这些高昂的成本往往导致严格的报销审查和使用限制。因此，经济拮据和医疗资源分配不均成为限制已获核准治疗方法广泛应用的主要障碍，并可能阻碍其在发展中经济体的整体市场渗透。

市场驱动因素

子宫内膜癌在全球的发生率不断上升，这主要归因于肥胖和METABOLIC INC.症候群的增加，也是推动市场扩张的主要因素。过多的脂肪组织会导致雌激素暴露增加，增加子宫恶性肿瘤的风险，尤其是在生活方式正在改变的已开发国家。这种日益严重的疾病负担不仅体现在病例数上，也体现在严重的后果上，因此需要紧急的临床介入。根据美国癌症协会于2024年1月发布的《2024年癌症统计》报告，子宫内膜癌的死亡率正以每年2%的速度增长，使其成为少数几种死亡率呈上升趋势的癌症类型之一。这一令人担忧的趋势正在加速对先进诊断筛检和强效治疗方案的需求，以便有效管理不断增长的患者群体。

同时，免疫疗法和标靶治疗的进步正在改变治疗模式，除传统化疗之外的治疗方法能够显着改善晚期癌症患者的存活预后。近期监管政策的调整扩大了免疫查核点抑制剂的应用范围，使其适用于更广泛的患者亚群，包括那些先前只能接受安宁疗护的患者。例如，葛兰素史克（GSK）在2024年8月发布的关于RUBY III期临床试验的新闻稿中指出，在一般患者人群中，多斯利单抗联合化疗与单独化疗相比，可降低31%的死亡风险。鑑于癌症的分子异质性，这种治疗方法策略的转变至关重要。Astra Zeneca在2024年6月发布的关于DUO-E临床试验的公告中指出，约20%至30%的子宫内膜癌患者存在错配修復缺陷（dMMR）疾病，这凸显了市场正朝着基于生物标誌物的精准医疗方向转变。

市场挑战

新型生物製药和免疫查核点抑制剂的高昂采集费用严重阻碍因素了子宫内膜癌市场的成长。这些高昂的价格需要保险公司和政府医疗系统进行严格评估，常常导致报销延迟或被拒绝。因此，对成本较为敏感的地方医疗系统通常会限制将这些昂贵的治疗方法纳入其标准药品目录，从而减少了製药厂商可触及的患者群体。

这种经济负担直接阻碍了市场发展，减缓了认证核可药在发展中国家市场和资源匮乏的公共医疗部门的推广速度。难以获得稳定的报销加剧了医疗服务分配的不公平，迫使大量患者依赖成本较低的治疗方法。根据美国癌症协会统计，2024年美国约有13,250人死于子宫内膜癌。这些死亡率统计数据凸显了一个关键的差距：先进治疗性介入面临的经济障碍限制了疾病负担减轻的潜力，并阻碍了整体市场产生收入。

市场趋势

定向抗体药物复合体（ADC）的兴起代表着治疗领域的一项重要进展，它提供了一种将强效细胞毒性药物直接递送至肿瘤相关抗原（如TROP2和HER2）的途径。对于接受铂类化疗或免疫疗法后病情进展的患者而言，这种方法满足了精准治疗方案的迫切需求，避免了标准疗法带来的全身毒性。透过利用特定的生物标记表达，ADC能够有效干预以往治疗选择有限的晚期疾病。根据2024年8月发表于《ASCO Post》的一篇题为「Sacituzumab govitecan治疗进行性子宫内膜癌」的报道，II期TROPiCS-03试验显示，在既往接受过治疗的进行性子宫内膜癌患者中，sacituzumab govitecan的客观缓解率达到了22%。

同时，人工智慧在病理学领域的应用正在改变诊断的准确性，它能够检测到传统组织学评估常常遗漏的高风险肿瘤特征。这些人工智慧工具正在协助精准分子分型的过渡，使临床医生能够根据復发风险对患者进行分层，而不仅依赖改进的分期系统。这项技术的整合对于区分形态相似的肿瘤丛集中的侵袭性亚型至关重要，从而增强个体化治疗策略。根据不列颠哥伦比亚大学于2024年6月发表的报导题为《科学家发现高风险子宫内膜癌》的文章，研究人员使用一种新型人工智慧模型成功识别出一种特定的高风险子宫内膜癌亚型，这种亚型无法透过传统病理学和分子诊断方法检测到。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球子宫内膜癌市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 癌症类型（子宫内膜癌、子宫肉瘤）
  • 依治疗方法（免疫疗法、放射线治疗、化疗、其他治疗方法）
  • 透过诊断方法（切片检查、骨盆超音波、子宫镜检查、 电脑断层扫描、其他诊断方法）
  • 依最终用途（医院、诊断影像中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美子宫内膜癌市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲子宫内膜癌市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区子宫内膜癌市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲子宫内膜癌市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲子宫内膜癌市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球子宫内膜癌市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Elekta
• Karyopharm Therapeutics Inc.
• Eisai Co., Ltd
• GSK plc
• Siemens Healthineers AG
• Johnson & Johnson
• Boston Scientific Corporation
• Pfizer Inc.
• Bayer AG
• Bristol-Myers Squibb Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Endometrial Cancer Market is anticipated to expand from USD 30.90 Billion in 2025 to USD 44.31 Billion by 2031, reflecting a compound annual growth rate of 6.19%. This market encompasses a diverse array of diagnostic tools and therapeutic options, including surgical procedures, chemotherapy, radiation therapy, and pharmacotherapies designed to treat malignancies of the uterine lining. The primary factors propelling market growth are the increasing global incidence of obesity and metabolic syndromes, which are major risk factors, as well as an aging female demographic prone to oncological diseases. Furthermore, the advent of targeted drug therapies and immunotherapies has significantly widened the treatment spectrum for patients suffering from recurrent or metastatic conditions. Data from the American Cancer Society indicates that an estimated 67,880 new cases of uterine cancer were projected for diagnosis in the United States in 2024, underscoring the escalating clinical need for effective management strategies.

Despite these advancements, the market faces a considerable hurdle due to the substantial costs linked to novel biologic agents and immune checkpoint inhibitors. These high expenses frequently result in strict reimbursement evaluations and restricted availability in areas with cost-conscious healthcare frameworks. Consequently, financial constraints and unequal access to medical care act as major impediments that may limit the broad adoption of approved treatments and hinder overall market penetration in developing economic regions.

Market Driver

The escalating global prevalence of endometrial cancer, largely fueled by rising rates of obesity and metabolic syndromes, serves as a primary driver for market expansion. Excess adipose tissue leads to increased estrogen exposure, thereby heightening the risk of malignant uterine conditions, especially in developed countries with changing lifestyle habits. This growing disease burden is evident not only in the number of cases but also in severity outcomes, requiring immediate clinical intervention. According to the 'Cancer Statistics, 2024' report by the American Cancer Society in January 2024, mortality rates for uterine corpus cancer are rising by 2% annually, identifying it as one of the few cancer types with increasing death rates. This concerning trend accelerates the demand for advanced diagnostic screenings and robust therapeutic measures to effectively manage the growing patient population.

Concurrently, progress in immunotherapy and targeted therapeutics is transforming treatment paradigms, transitioning beyond conventional chemotherapy to provide better survival outcomes for advanced disease stages. Recent regulatory achievements have extended the use of immune checkpoint inhibitors to a wider range of patient subgroups, including those who previously had only palliative options. For example, a press release from GSK in August 2024 regarding the RUBY phase III trial highlighted that combining dostarlimab with chemotherapy resulted in a 31% reduction in the risk of death compared to chemotherapy alone in the general patient population. This evolution in therapy is vital given the molecular heterogeneity of the cancer; an AstraZeneca announcement in June 2024 concerning the DUO-E trial noted that approximately 20% to 30% of endometrial cancer patients have mismatch repair deficient (dMMR) disease, emphasizing the significant market shift toward precision medicine based on biomarkers.

Market Challenge

The substantial acquisition costs associated with new biologic agents and immune checkpoint inhibitors function as a major constraint on the growth of the endometrial cancer market. These high prices require intense evaluation by insurance providers and government healthcare schemes, often leading to delays or denials of reimbursement coverage. As a result, healthcare systems in regions sensitive to costs frequently limit the inclusion of these premium therapies in their standard drug lists, thereby reducing the accessible patient population for pharmaceutical manufacturers.

This economic strain directly impedes market development by slowing the uptake of approved drugs in developing markets and under-resourced public health sectors. The difficulty in obtaining consistent reimbursement results in unequal care delivery, leaving a large segment of the patient population dependent on older, less costly treatment methods. According to the American Cancer Society, approximately 13,250 deaths from uterine body cancers were projected to occur in the United States in 2024. This mortality statistic highlights a critical gap where financial barriers to advanced therapeutic interventions restrict the potential for reducing disease burden and limit overall market revenue generation.

Market Trends

The rise of Antibody-Drug Conjugates (ADCs) for targeted delivery marks a significant evolution in the therapeutic landscape, offering a method to transport potent cytotoxic agents directly to tumor-associated antigens like TROP2 and HER2. This approach addresses a crucial unmet need for patients whose disease progresses following platinum-based chemotherapy and immunotherapy, providing a precise alternative to the systemic toxicities of standard treatments. By utilizing specific biomarker expression, ADCs facilitate effective intervention in advanced disease scenarios where options were previously restricted. As reported by The ASCO Post in August 2024 regarding the 'Sacituzumab Govitecan in Advanced Endometrial Cancer' report, the phase II TROPiCS-03 trial showed that sacituzumab govitecan achieved an objective response rate of 22% in patients with advanced endometrial cancer who had undergone prior therapies.

Simultaneously, the application of artificial intelligence in pathology is transforming diagnostic precision by detecting high-risk tumor characteristics that often evade traditional histological evaluation. These AI-powered tools assist in the shift toward accurate molecular classification, enabling clinicians to categorize patients based on recurrence risk more effectively than improved staging systems alone. This integration of technology is essential for differentiating aggressive subtypes within morphologically similar tumor clusters, thereby enhancing personalized care strategies. According to a June 2024 article from the University of British Columbia titled 'Scientists discover high-risk form of endometrial cancer,' researchers employed a new AI model to identify a specific high-risk subset of endometrial cancer that would otherwise remain undetected by conventional pathology and molecular diagnostics.

Key Market Players

• Elekta
• Karyopharm Therapeutics Inc.
• Eisai Co., Ltd
• GSK plc
• Siemens Healthineers AG
• Johnson & Johnson
• Boston Scientific Corporation
• Pfizer Inc.
• Bayer AG
• Bristol-Myers Squibb Company

Report Scope

In this report, the Global Endometrial Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endometrial Cancer Market, By Cancer Type

• Endometrial Carcinoma
• Uterine Sarcomas

Endometrial Cancer Market, By Therapy

• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Other Types of Therapies

Endometrial Cancer Market, By Diagnosis Method

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT scan
• Other Diagnosis Methods

Endometrial Cancer Market, By End Use

• Hospitals
• Imaging Centers
• Others

Endometrial Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endometrial Cancer Market.

Available Customizations:

Global Endometrial Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Endometrial Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Endometrial Carcinoma, Uterine Sarcomas)
  • 5.2.2. By Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies)
  • 5.2.3. By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods)
  • 5.2.4. By End Use (Hospitals, Imaging Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Endometrial Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapy
  • 6.2.3. By Diagnosis Method
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Endometrial Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Diagnosis Method
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Endometrial Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Diagnosis Method
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Endometrial Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Diagnosis Method
      • 6.3.3.2.4. By End Use

7. Europe Endometrial Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapy
  • 7.2.3. By Diagnosis Method
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Endometrial Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Diagnosis Method
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Endometrial Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Diagnosis Method
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Endometrial Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Diagnosis Method
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Endometrial Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Diagnosis Method
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Endometrial Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Diagnosis Method
      • 7.3.5.2.4. By End Use

8. Asia Pacific Endometrial Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapy
  • 8.2.3. By Diagnosis Method
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Endometrial Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Diagnosis Method
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Endometrial Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Diagnosis Method
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Endometrial Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Diagnosis Method
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Endometrial Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Diagnosis Method
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Endometrial Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Diagnosis Method
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Endometrial Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapy
  • 9.2.3. By Diagnosis Method
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Endometrial Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Diagnosis Method
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Endometrial Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Diagnosis Method
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Endometrial Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Diagnosis Method
      • 9.3.3.2.4. By End Use

10. South America Endometrial Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapy
  • 10.2.3. By Diagnosis Method
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Endometrial Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Diagnosis Method
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Endometrial Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Diagnosis Method
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Endometrial Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Diagnosis Method
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Endometrial Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Elekta
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Karyopharm Therapeutics Inc.
• 15.3. Eisai Co., Ltd
• 15.4. GSK plc
• 15.5. Siemens Healthineers AG
• 15.6. Johnson & Johnson
• 15.7. Boston Scientific Corporation
• 15.8. Pfizer Inc.
• 15.9. Bayer AG
• 15.10. Bristol-Myers Squibb Company

16. Strategic Recommendations

17. About Us & Disclaimer